Company intelligence / Profile preview
Daewoong Infion
- Ownership
- Private
- Development stage
- Commercial
Overview
Daewoong Infion operates Indonesia’s first biopharmaceutical factory producing biological products and biosimilars from drug substance to finished product. Its lead commercial product is erythropoietin alpha (“Epodion”), the first locally manufactured biological in Indonesia. The company has a modern GMP-certified facility and focuses on affordable biologics for local and export markets. It collaborates with academic institutions and offers CMO services.
- Therapeutic areas
- HematologyEndocrinologyDermatology
- Modalities
- Recombinant proteinBiologicBiosimilar
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on Daewoong Infion.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Daewoong Infion.